全文获取类型
收费全文 | 58700篇 |
免费 | 5339篇 |
国内免费 | 448篇 |
专业分类
耳鼻咽喉 | 330篇 |
儿科学 | 2543篇 |
妇产科学 | 2327篇 |
基础医学 | 19651篇 |
口腔科学 | 658篇 |
临床医学 | 3524篇 |
内科学 | 9578篇 |
皮肤病学 | 1261篇 |
神经病学 | 7193篇 |
特种医学 | 1420篇 |
外科学 | 3907篇 |
综合类 | 942篇 |
现状与发展 | 7篇 |
预防医学 | 1978篇 |
眼科学 | 1026篇 |
药学 | 2142篇 |
3篇 | |
中国医学 | 57篇 |
肿瘤学 | 5940篇 |
出版年
2023年 | 2074篇 |
2022年 | 2350篇 |
2021年 | 2419篇 |
2020年 | 2963篇 |
2019年 | 2233篇 |
2018年 | 2318篇 |
2017年 | 2628篇 |
2016年 | 2636篇 |
2015年 | 2746篇 |
2014年 | 4667篇 |
2013年 | 3830篇 |
2012年 | 2445篇 |
2011年 | 2575篇 |
2010年 | 3466篇 |
2009年 | 3295篇 |
2008年 | 1983篇 |
2007年 | 2003篇 |
2006年 | 1741篇 |
2005年 | 1476篇 |
2004年 | 1203篇 |
2003年 | 1112篇 |
2002年 | 1149篇 |
2001年 | 1168篇 |
2000年 | 1034篇 |
1999年 | 1036篇 |
1998年 | 732篇 |
1997年 | 624篇 |
1996年 | 618篇 |
1995年 | 633篇 |
1994年 | 499篇 |
1993年 | 489篇 |
1992年 | 463篇 |
1991年 | 389篇 |
1990年 | 371篇 |
1989年 | 330篇 |
1988年 | 363篇 |
1987年 | 319篇 |
1986年 | 127篇 |
1985年 | 177篇 |
1984年 | 183篇 |
1983年 | 132篇 |
1982年 | 154篇 |
1981年 | 139篇 |
1980年 | 132篇 |
1979年 | 141篇 |
1978年 | 126篇 |
1977年 | 108篇 |
1976年 | 113篇 |
1975年 | 85篇 |
1974年 | 111篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
23.
24.
《The Canadian journal of cardiology》2022,38(1):49-58
BackgroundDilated cardiomyopathy (DCM) is a well described entity for heart failure (HF) with reduced left ventricular ejection fraction (LVEF). Recently, drugs and other substance of abuse have been recognised as potential triggers for DCM. The aim of this study was to assess the survival in patients ≤ 65 years of age with toxic cardiomyopathy (TCM). Left ventricular remodelling and the potential usefulness of left ventricular assist devices (LVADs) was also assessed.MethodsThis was a single-centre retrospective study from January 2003 to August 2019 of 553 patients ≤ 65 years old with LVEF < 40% at a tertiary-care cardiology centre.ResultsA total of 201 patients (36%) had a diagnosis of idiopathic DCM. Further analysis identified 38 patients (19%) for which a TCM was the most likely etiology (amphetamine [50%], cocaine [37%], anabolic steroids [8%], and energy drinks [5%]). Despite a mean LVEF of 17 ± 8% at presentation, most patients (n = 27; 71%) had event-free survival with guideline-directed medical therapy, and 61% (n = 23) recovered an LVEF ≥ 40% after a median follow-up of 21 ± 23 months. Seven patients (18%) required an LVAD and 1 patient (3%) a transplantation. All LVADs were explanted or decommissioned after partial or complete LVEF recovery after a median support time of 11 ± 4 months.ConclusionsTCM induced by substance abuse is a frequent cause of HF, accounting for almost 20% of patients ≤ 65 years of age with DCM of unknown etiology. Treatment must be tailored on an individual basis. Mechanical circulatory support demonstrated its usefulness in carefully selected patients. 相似文献
25.
《European journal of medical genetics》2022,65(6):104495
Spondyloepimetaphyseal dysplasias (SEMDs) belong to a clinically and genetically heterogeneous group of inherited skeletal disorders defined by a defect in the growth and shape of vertebrae, epiphyses and metaphyses. Rhizomelic SEMD is characterized by a disproportionate small stature caused by severe shortening and deformation of the limbs’ proximal bones, with the cranio-facial sphere unaffected. We report a second individual, an 8-year-old girl, with autosomal recessive rhizomelic SEMD associated with a homozygous exonic missense variant, c.226G > A p.(Glu76Lys), in GNPNAT1 identified by trio genome sequencing. Our data corroborate the recent findings of Ain et al. and further delineate the clinical and radiographic features of this form of SEMD associated with rhizomelic dysplasia while outlining a potential hotspot in this newly described genetic disorder. 相似文献
26.
27.
The study aimed to evaluate the impact of the updated 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) testing in invasive breast cancer compared with previous 2013 guidelines. Between Jan 2014 and May 2020, 3364 consecutive invasive breast carcinomas with concurrent HER2 immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) results were retrospectively reviewed for HER2 status. Both 2013 and 2018 testing criteria were applied to establish the HER2 status. The testing algorithms involved testing of invasive breast carcinomas by IHC, with equivocal results being reflexed to FISH assays. Concordance rate improved from 92.7% to 94.1% in the non-equivocal IHC cases with the 2018 guidelines. Comparing 2013 versus 2018 criteria, HER2 non-amplified cases increased significantly from 73.7% (n = 2478) to 76.8% (n = 2585), HER2 amplified cases remained similar from 23.4% (n = 789) to 23.2% (n = 779) while equivocal cases decreased from 2.9% (n = 97) to 0% with the new guidelines. Thus, 107 cases (3.2%) were reclassified from HER2 equivocal (n = 97) and amplified (n = 10) to non-amplified with the updated 2018 guidelines. Under the 2018 criteria, a total of 259 cases (7.7%) belonged to the uncommon categories (groups 2 to 4), with group 3 being the most frequent (4.6%), followed by group 4 (2.9%) and group 2 (0.2%). Implementation of 2018 guidelines resulted in a significant increase in HER2 non-amplified cases, mainly due to the abolishment of the equivocal FISH group. This has helped resolve the clinical practice dilemma by providing a more definitive HER2 gene status. 相似文献
28.
29.
30.